King Wealth Genmab A/S Transaction History

King Wealth

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$32.88 - $44.57 $328,800 - $445,700	-10,000 Reduced 37.18%	16,897 $690,000
Q1 2021 May 14, 2021	BUY	$30.92 - $44.4 $401,960 - $577,200	13,000 Added 93.55%	26,897 $883,000
Q1 2020 May 13, 2020	SELL	$17.15 - $25.22 $137,200 - $201,760	-8,000 Reduced 36.53%	13,897 $294,000
Q4 2019 Feb 13, 2020	SELL	$18.88 - $24.14 $94,400 - $120,700	-5,000 Reduced 18.59%	21,897 $489,000
Q3 2019 Nov 13, 2019	BUY	$18.0 - $21.38 $484,146 - $575,057	26,897 New	26,897 $545,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of King Wealth, based on Form 13F filings with the SEC.

Stay updated on King Wealth with notifications on news.